Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265667 · ClinicalTrials.gov registry record · Phase 2
Trial of CF101 to Treat Patients With Psoriasis
A Phase 2 study, sponsored by Can-Fite BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 293
- Enrollment target
NCT01265667 is a Phase 2 study that has completed, run by Can-Fite BioPharma. The registered enrollment target is 293 participants.
The verdict
NCT01265667, a Phase 2 study, has completed, sponsored by Can-Fite BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 293 participants
- Enrollment target
Study Summary
Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
Interventions
- DRUG Placebo
- DRUG CF101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265667
The ClinicalTrials.gov registry entry for NCT01265667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Can-Fite BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01265667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265667 about?
NCT01265667 is a clinical study titled "Trial of CF101 to Treat Patients With Psoriasis". Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
What is the current status of trial NCT01265667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2011-07. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01265667?
The interventions under investigation include: Placebo (DRUG), CF101 (DRUG).
Who is sponsoring clinical trial NCT01265667?
This trial is sponsored by Can-Fite BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.